Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsLatham, Ned H
Doyle, Joseph S
Palmer, Anna Y
Vanhommerig, Joost W
Altice, Frederick L
Falade-Nwulia, Oluwaseun O
Hellard, Margaret E
MetadataShow full item record
CitationLatham NH, Doyle JS, Palmer AY, et al. Staying hepatitis C negative: A systematic review and meta‐analysis of cure and reinfection in people who inject drugs. Liver Int. 2019;39:2244–2260. https://doi.org/10.1111/liv.14152
AbstractBACKGROUND AND AIMS: Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C. However, there is concern that cure rates may be lower, and reinfection rates higher, among people who inject drugs. We conducted a systematic review of treatment outcomes achieved with DAAs in people who inject drugs (PWID). METHODS: A search strategy was used to identify studies that reported sustained viral response (SVR), treatment discontinuation, adherence or reinfection in recent PWID and/or opioid substitution therapy (OST) recipients. Study quality was assessed using the Newcastle-Ottawa Scale. Meta-analysis of proportions was used to estimate pooled SVR and treatment discontinuation rates. The pooled relative risk of achieving SVR and pooled reinfection rate were calculated using generalized mixed effects linear models. RESULTS: The search identified 8075 references; 26 were eligible for inclusion. The pooled SVR for recent PWID was 88% (95% CI, 83%-92%) and 91% (95% CI 88%-95%) for OST recipients. The relative risk of achieving SVR for recent PWID compared to non-recent PWID was 0.99 (95% CI, 0.94-1.06). The pooled treatment discontinuation was 2% (95% CI, 1%-4%) for both recent PWID and OST recipients. Amongst recent PWID, the pooled incidence of reinfection was 1.94 per 100 person years (95% CI, 0.87-4.32). In OST recipients, the incidence of reinfection was 0.55 per 100 person years (95% CI, 0.17-1.76). CONCLUSIONS: Treatment outcomes were similar in recent PWID compared to non-PWID treated with DAAs. People who report recent injecting or OST recipients should not be excluded from hepatitis C treatment.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
Rights© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
- Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
- Authors: Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, Zeuzem S, Herrmann E, Vermehren J
- Issue date: 2020 May 23
- Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
- Authors: Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, Darvishian M, Gilbert M, Wong J, Chapinal N, Binka M, Alvarez M, Tyndall MW, Krajden M, Janjua NZ, BC Hepatitis Testers Cohort Team.
- Issue date: 2018 Nov
- Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
- Authors: Rahman M, Janjua NZ, Shafiq TKI, Chowdhury EI, Sarker MS, Khan SI, Reza M, Faruque MO, Kabir A, Anis AH, Azim T
- Issue date: 2019 Dec
- Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.
- Authors: Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME
- Issue date: 2013 Aug
- Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
- Authors: Macías J, Morano LE, Téllez F, Granados R, Rivero-Juárez A, Palacios R, Ríos M, Merino D, Pérez-Pérez M, Collado A, Figueruela B, Morano A, Freyre-Carrillo C, Martín JM, Rivero A, García F, Pineda JA, HEPAVIR group from the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) and the GEHEP group from the Sociedad Española de Enfermedades Infecciosas y Microbiología (SEIMC).
- Issue date: 2019 Jul